Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. [electronic resource]
Producer: 20180917Description: 302-309 p. digitalISSN:- 1473-5687
- Adult
- Antiviral Agents -- adverse effects
- Carbamates
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- classification
- Hepatitis C, Chronic -- complications
- Humans
- Imidazoles -- adverse effects
- Interferon alpha-2
- Interferon-alpha -- adverse effects
- Isoquinolines -- adverse effects
- Liver Cirrhosis -- virology
- Male
- Middle Aged
- Pilot Projects
- Pyrrolidines
- RNA, Viral -- blood
- Recombinant Proteins -- adverse effects
- Ribavirin -- adverse effects
- Sulfonamides -- adverse effects
- Sustained Virologic Response
- Treatment Failure
- Treatment Outcome
- Valine -- analogs & derivatives
- Viral Load -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.